Early Breast Cancer in Older Patients: Standard Chemotherapy Versus Capecitabine

In older women with early breast cancer, standard adjuvant chemotherapy is superior to capecitabine for recurrence-free survival. These results come from the 10-year follow-up of the Cancer and Leukemia Group B (CALGB) 49907 trial, which focused on patients age 65 and older. For this study, 633 patients were randomized to receive either standard adjuvant chemotherapy, consisting of physician's choice of cyclophosphamide/methotrexate/fluorouracil or cyclophosphamide/doxorubicin, or capecitabine. ...
Continue reading

In Endometrial Cancer, Chemoradiotherapy Improves Outcomes

​ Adjuvant chemoradiotherapy increases five-year overall survival and failure-free survival compared with radiotherapy alone for women with high-risk endometrial cancer, report the researchers of the phase 3 PORTEC-3 trial in their updated analysis, which has now been published in The Lancet Oncology . Around 15% to 20% of patients with endometrial cancer are considered to have high-risk endometrial cancer, defined as endometrioid endometrial cancer stage 1, grade 3 with deep invasion; stage II ...
Continue reading

Artificial Intelligence: Useful for Designing Clinical Trials

Due to lackluster recruiting techniques, a suboptimal number of patients are selected to participate in clinical trials. In addition, the researchers often have limited ability to observe and coach patients during clinical trials. These factors contribute to high clinical trial failure rates, which have a negative impact on the drug development cycle, not to mention 10 to 15 years and hundreds of millions of dollars wasted. However, scientists have proposed a potential solution to this problem: ...
Continue reading

Mystery Behind 5-FU Resistance Solved

According to a recent study, the Bok protein from the BCL-2 protein family was discovered to play a role in resistance to the chemotherapy drug 5-fluorouracil (5-FU). An antimetabolite, 5-FU is an important drug used for many cancers including colorectal cancer, breast cancer, gastrointestinal cancer, head and neck cancer, neuroendocrine tumors, thymic cancers, cervical cancer, and bladder cancer, among others. 5-Fluorouracil works by incorporating toxic substances into cancerous cells, disrupti...
Continue reading

Paclitaxel for Stage IV Anal Cancer

Even though anal cancer only accounts for 2.7% of all digestive malignancies, with only 8,300 new cases diagnosed each year, its incidence has been rising over the last 30 years. This is due to a variety of factors, including human papillomavirus (HPV) infection, cigarette smoking, and infection with human immunodeficiency virus (HIV), among others. The treatment for locoregional squamous cell cancer of the anal canal is well established, consisting of the combined therapy of 5-fluorouracil (5-F...
Continue reading

© Copyright 2019 i3 Health. All rights reserved.